| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
50.94
|
|
2
|
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
41.47
|
|
3
|
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
26.95
|
|
4
|
Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.
|
Lancet
|
2015
|
7.99
|
|
5
|
UK health performance: findings of the Global Burden of Disease Study 2010.
|
Lancet
|
2013
|
6.11
|
|
6
|
Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.
|
J Allergy Clin Immunol
|
2004
|
5.80
|
|
7
|
Penicillin to prevent recurrent leg cellulitis.
|
N Engl J Med
|
2013
|
4.84
|
|
8
|
Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process.
|
J Invest Dermatol
|
2010
|
3.09
|
|
9
|
Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis.
|
Lancet
|
2002
|
3.07
|
|
10
|
Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.
|
BMJ
|
2005
|
2.59
|
|
11
|
Have you ever seen an Asian/Pacific Islander?
|
Arch Dermatol
|
2002
|
2.11
|
|
12
|
The increasing importance of systematic reviews in clinical dermatology research and publication.
|
J Invest Dermatol
|
2006
|
2.05
|
|
13
|
Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three.
|
J Allergy Clin Immunol
|
2009
|
1.99
|
|
14
|
A randomised controlled trial of ion-exchange water softeners for the treatment of eczema in children.
|
PLoS Med
|
2011
|
1.90
|
|
15
|
The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective.
|
Arch Dermatol
|
2004
|
1.82
|
|
16
|
What are the best outcome measurements for atopic eczema? A systematic review.
|
J Allergy Clin Immunol
|
2007
|
1.79
|
|
17
|
Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials.
|
Vet Dermatol
|
2010
|
1.72
|
|
18
|
IJD(®): Consorting with CONSORT 2010.
|
Indian J Dermatol
|
2013
|
1.53
|
|
19
|
Interventions for preventing occupational irritant hand dermatitis.
|
Cochrane Database Syst Rev
|
2010
|
1.45
|
|
20
|
Bleach baths to reduce severity of atopic dermatitis colonized by Staphylococcus.
|
Arch Dermatol
|
2010
|
1.44
|
|
21
|
Evidence-based dermatology: number needed to treat and its relation to other risk measures.
|
J Am Acad Dermatol
|
2006
|
1.43
|
|
22
|
Tuberculosis, bacillus Calmette-Guérin vaccination, and allergic disease: findings from the International Study of Asthma and Allergies in Childhood Phase Two.
|
Pediatr Allergy Immunol
|
2011
|
1.42
|
|
23
|
In a patient with toxic epidermal necrolysis, does intravenous immunoglobulin improve survival compared with supportive care?
|
Arch Dermatol
|
2011
|
1.39
|
|
24
|
What is meant by a "flare" in atopic dermatitis? A systematic review and proposal.
|
Arch Dermatol
|
2006
|
1.19
|
|
25
|
Diagnosis of tumors during tissue-conserving surgery with integrated autofluorescence and Raman scattering microscopy.
|
Proc Natl Acad Sci U S A
|
2013
|
1.17
|
|
26
|
Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial.
|
Lancet
|
2004
|
1.11
|
|
27
|
The value of the pragmatic-explanatory continuum indicator summary wheel in an ongoing study: the bullous pemphigoid steroids and tetracyclines study.
|
Trials
|
2012
|
1.10
|
|
28
|
The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two.
|
J Allergy Clin Immunol
|
2007
|
1.08
|
|
29
|
Full disclosure--nothing less will do.
|
J Invest Dermatol
|
2007
|
1.07
|
|
30
|
Interventions to reduce Staphylococcus aureus in the management of atopic eczema.
|
Cochrane Database Syst Rev
|
2008
|
1.02
|
|
31
|
Does "autoreactivity" play a role in atopic dermatitis?
|
J Allergy Clin Immunol
|
2012
|
0.96
|
|
32
|
How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies.
|
J Allergy Clin Immunol
|
2012
|
0.96
|
|
33
|
Prospective registration and outcome-reporting bias in randomized controlled trials of eczema treatments: a systematic review.
|
J Invest Dermatol
|
2012
|
0.94
|
|
34
|
The role of furry pets in eczema: a systematic review.
|
Arch Dermatol
|
2007
|
0.93
|
|
35
|
Feasibility study to inform the design of a UK multi-centre randomised controlled trial of prophylactic antibiotics for the prevention of recurrent cellulitis of the leg.
|
Trials
|
2007
|
0.93
|
|
36
|
What is the point of databases of reviews for dermatology if all they compile is "insufficient evidence"?
|
J Am Acad Dermatol
|
2004
|
0.93
|
|
37
|
UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial.
|
Trials
|
2012
|
0.91
|
|
38
|
Overview of Reviews The prevention of eczema in infants and children: an overview of Cochrane and non-Cochrane reviews.
|
Evid Based Child Health
|
2011
|
0.91
|
|
39
|
Dietary supplements for established atopic eczema.
|
Cochrane Database Syst Rev
|
2012
|
0.91
|
|
40
|
The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma.
|
Trials
|
2010
|
0.88
|
|
41
|
Mapping randomized controlled trials of treatments for eczema--the GREAT database (the Global Resource of EczemA Trials: a collection of key data on randomized controlled trials of treatments for eczema from 2000 to 2010).
|
BMC Dermatol
|
2011
|
0.88
|
|
42
|
Validation of epidemiological tools for eczema diagnosis in Brazilian children: the ISAAC's and UK Working Party's criteria.
|
BMC Dermatol
|
2010
|
0.86
|
|
43
|
House dust mite reduction and avoidance measures for treating eczema.
|
Cochrane Database Syst Rev
|
2015
|
0.86
|
|
44
|
Intervention implementation research: an exploratory study of reduction strategies for occupational contact dermatitis in the printing industry.
|
Contact Dermatitis
|
2007
|
0.85
|
|
45
|
Chinese herbal medicine for atopic eczema.
|
Cochrane Database Syst Rev
|
2013
|
0.85
|
|
46
|
What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial.
|
BMC Dermatol
|
2012
|
0.84
|
|
47
|
Mapping systematic reviews on atopic eczema--an essential resource for dermatology professionals and researchers.
|
PLoS One
|
2013
|
0.84
|
|
48
|
Introducing the National Library for Health Skin Conditions Specialist Library.
|
BMC Dermatol
|
2005
|
0.83
|
|
49
|
Evening primrose oil for atopic dermatitis.
|
BMJ
|
2003
|
0.81
|
|
50
|
Natural history of atopic dermatitis and its relationship to serum total immunoglobulin E in a population-based birth cohort study.
|
Pediatr Allergy Immunol
|
2004
|
0.79
|
|
51
|
Problems in the reporting of acne clinical trials: a spot check from the 2009 Annual Evidence Update on Acne Vulgaris.
|
Trials
|
2010
|
0.79
|
|
52
|
When inferiority meets non-inferiority: implications for interim analyses.
|
Clin Trials
|
2012
|
0.78
|
|
53
|
Reporting clinical trials: why one plus one does not equal two.
|
J Am Acad Dermatol
|
2009
|
0.77
|
|
54
|
WITHDRAWN: Chinese herbal medicine for atopic eczema.
|
Cochrane Database Syst Rev
|
2013
|
0.77
|
|
55
|
Specific allergen immunotherapy for the treatment of atopic eczema.
|
Cochrane Database Syst Rev
|
2016
|
0.76
|
|
56
|
Educational programmes for young people with eczema.
|
BMJ
|
2006
|
0.75
|
|
57
|
Evidence-based veterinary dermatology--better to light a candle than curse the darkness.
|
Vet Dermatol
|
2010
|
0.75
|
|
58
|
Clinical evidence epistemology.
|
J Invest Dermatol
|
2007
|
0.75
|
|
59
|
The Cochrane Skin Group: a vanguard for developing and promoting evidence-based dermatology.
|
J Evid Based Med
|
2013
|
0.75
|
|
60
|
Alitretinoin as a potential advance in the management of severe chronic hand eczema.
|
Arch Dermatol
|
2009
|
0.75
|
|
61
|
Self-regulation in hospital waiting lists.
|
J R Soc Med
|
2002
|
0.75
|
|
62
|
A scientific look at seasonality of symptom severity in atopic dermatitis.
|
J Invest Dermatol
|
2005
|
0.75
|
|
63
|
Penicillin to prevent recurrent leg cellulitis.
|
N Engl J Med
|
2013
|
0.75
|
|
64
|
Therapeutic use of stories for children with atopic eczema and other chronic skin conditions.
|
Pediatr Dermatol
|
2013
|
0.75
|
|
65
|
Current management of atopic eczema.
|
Practitioner
|
2002
|
0.75
|
|
66
|
Democratizing the clinical trials agenda in dermatology.
|
J Invest Dermatol
|
2013
|
0.75
|